Published on June 4, 2021
THURSDAY, June 3, 2021 (NBC)—By the time Michael Rosenblum’s prostate cancer was discovered, it was already at a late stage. He’d initially sought medical help because of excruciating back pain, but, during an exam, doctors found a tumor on his spine and tests revealed a skyrocketing prostate-specific antigen, or PSA, score. Chemotherapy didn’t help much, so when doctors offered the opportunity to be in a clinical trial for a new experimental treatment, Rosenblum jumped at it.
The trial was investigating a new, potentially groundbreaking type of treatment for prostate cancer, a therapy that specifically targets a protein on the cancer cells. The treatment, part of a new class of liquid radiation drugs, obliterates most prostate cancer cells without hurting the surrounding tissue.
North Dakota could eradicate cervical cancer thanks to high HPV vaccination rates, health department says
May 31, Grand Forks Herald
Breast cancer leads Latinas’ cancer deaths
June 3, Axios
Supreme Court will not take up Johnson & Johnson challenge of $2.1 billion cancer case award
June 1, The Washington Post
The Prevent Cancer Foundation applauds the Senate introduction of the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873). This welcome development follows the House’s introduction of H.R. 1946 in March and strong support of the bipartisan legislation from more than 300 organizations across all 50 states. Read More.